Search research articles
Contact Us
Filters
Showing results (171-180 of 224) with videos related to
Page
of 23
Sort By:
Cancer Immunology, Immunotherapy : CII
|
April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Sabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2022
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study
Alfredo Addeo, Sacha I Rothschild, Lisa Holer, et al.
JCO Precision Oncology
|
November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.
JMIR Research Protocols
|
October 18, 2023
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial
André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, et al.
International Immunopharmacology
|
July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
Giuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
European Radiology
|
September 8, 2025
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods
Almudena Fuster-Matanzo, Alfonso Picó-Peris, Fuensanta Bellvís-Bataller, et al.
International Journal of Molecular Sciences
|
January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
British Journal of Cancer
|
May 15, 2024
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
Umberto Malapelle, Natasha Leighl, Alfredo Addeo, et al.
Translational Lung Cancer Research
|
October 17, 2022
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study
Kai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, et al.
Cancer Immunology, Immunotherapy : CII
|
November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 224) with videos related to
Sort By:
Page
of 23
Cancer Immunology, Immunotherapy : CII
|
April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Sabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2022
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study
Alfredo Addeo, Sacha I Rothschild, Lisa Holer, et al.
JCO Precision Oncology
|
November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis
Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.
JMIR Research Protocols
|
October 18, 2023
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial
André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, et al.
International Immunopharmacology
|
July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
Giuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
European Radiology
|
September 8, 2025
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods
Almudena Fuster-Matanzo, Alfonso Picó-Peris, Fuensanta Bellvís-Bataller, et al.
International Journal of Molecular Sciences
|
January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
British Journal of Cancer
|
May 15, 2024
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
Umberto Malapelle, Natasha Leighl, Alfredo Addeo, et al.
Translational Lung Cancer Research
|
October 17, 2022
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study
Kai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, et al.
Cancer Immunology, Immunotherapy : CII
|
November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Page
of 23